Sputnik V to be $300 million boost to Dr Reddy's
The company has got permission from the Drug Controller General of India (DCGI) to import the vaccine. Reddy's is also going to tap domestically contract manufactured vaccines as and when companies are allowed to start commercial manufacturing in India
PB Jayakumar | April 14, 2021 | Updated 17:35 IST
Dr Reddy's to market and distribute 250 doses of Sputnik V
Dr Reddy's Laboratories, which has exclusive marketing and distribution rights for the first 250 million doses of Russia's Sputnik V vaccines in India, may get potential upside revenues of $300 million from the contract, estimates an analyst report.
The government's Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has recently recommended Russian Direct Investment Fund (RDIF)'s Sputnik V vaccine for Emergency Use Authorisation (EUA) in India, subject to satisfactory immunogenicity data submission.